CCM
EGRX

Corsair Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Corsair Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,067
Closed -$1.19M – 86
2017
Q2 		$1.19M Buy
15,067
+1,263
+9% +$103K 0.22% 57
2017
Q1 		$1.15M Sell
13,804
-4,371
-24% -$325K 0.2% 54
2016
Q4 		$1.44M Sell
18,175
-473
-3% -$34.4K 0.25% 56
2016
Q3 		$1.3M Buy
+18,648
New +$1.03M 0.22% 54

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Corsair Capital Management's EGRX Position: Q3 2017 in Review

Corsair Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 15,067 shares — an estimated $1.19M sold.

Corsair Capital Management first reported a position in EGRX in Q3 2016 and held it in 4 quarters. The position peaked at $1.44M in Q4 2016. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

  • Corsair Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Corsair Capital Management sold 15,067 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.19M.
  • Corsair Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 4 quarters.
  • Corsair Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1.44M in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Corsair Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.